Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is the Biotech IPO Window Closing?

This article was originally published in Scrip

Executive Summary

Drug developers are filing for initial public offerings at a brisk pace in October despite falling biotechnology stock values and the struggle to price first-time offerings attractively, which begs the question: Are biotech companies afraid that the IPO window is about to close?

Advertisement

Related Content

Immuno-Oncology 2.0 Roundtable: Scientific And Pricing Challenges Can't Slow New Therapies
Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field
Wave Keeps Neuro Focus Via Pfizer Collaboration For Five Metabolic Targets
AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel